Synairgen names Joseph Colliver as CFO
11th Oct 2023 10:26
(Sharecast News) - Drug discovery firm Synairgen revealed on Wednesday that it had tapped Joseph Colliver to take over as chief financial officer.
Read moreSynairgen posts positive results for phase 2 trial with SNG001 against Covid-19
4th Oct 2022 08:00
(Sharecast News) - Synairgen announced positive results for its inhaled antiviral protein treatment interferon beta against Covid-19.
Read moreSynairgen unveils positive clinical trial data
7th Sep 2022 07:59
(Sharecast News) - Respiratory drug discovery firm Synairgen has announced positive findings from a clinical trial into its experimental antiviral treatment.
Read moreSynairgen to collaborate with University of Southampton on observational study
5th Sep 2022 10:42
(Sharecast News) - Drug discovery outfit Synairgen will collaborate with the University of Southampton on an observational study aimed at exploring and better understanding acute respiratory viral infections and recovery.
Read moreSynairgen posts positive clinical trial data for SNG001
16th May 2022 15:23
(Sharecast News) - Shares of Synairgen caught a bid following the release of clinical trial results which appeared to show that its SNG001 formulation against Covid-19 might lower the risk of severe disease or death in the most at risk patients.
Read moreSynairgen falls as patient recruitment halted on Covid-19 trial
17th Mar 2022 12:32
(Sharecast News) - Inhaled antiviral treatment developer Synairgen said on Thursday that the US National Institute of Allergy and Infectious Diseases (NIAID) has halted all patient recruitment in its phase 2 and 3 Covid-19 trial, which included the assessment of its 'SNG001' treatment.
Read moreSynairgen asked to pause activities on Covid-19 treatment trial
3rd Mar 2022 12:20
(Sharecast News) - Synairgen announced on Thursday that it was pausing clinical trial activities on its 'SNG001' compound in the treatment of Covid-19, at the behest of American authorities.
Read moreSynairgen shares plunge as Covid-19 treatment trial fails
21st Feb 2022 09:27
(Sharecast News) - Synairgen announced on Monday that the international phase 3 trial of its SNG001 antiviral inhalation in patients hospitalised with Covid-19 did not meet its primary or key secondary endpoints.
Read moreSynairgen secures patients for phase III study of Covid treatment, shares jump
11th Nov 2021 13:03
(Sharecast News) - Shares in Synairgen rallied on Thursday,after the respiratory drug specialist confirmed it was starting a Phase III study into a potential Covid-19 treatment.
Read moreSynairgen drug proves effective against Covid variants in lab tests
24th May 2021 08:33
(Sharecast News) - A drug being developed by Synairgen to treat severe lung infections has shown promising laboratory results against emerging variants of Covid-19, the biotech announced on Monday.
Read moreSynairgen confirms start of dosing in Covid-19 trial
15th Feb 2021 11:57
(Sharecast News) - Respiratory drug discovery and development company Synairgen announced on Monday that dosing has started in the inhaled interferon beta formulation 'SNG001' sub-study of the 'ACTIV-2' phase 2 and 3 trial, evaluating patients with mild-to-moderate Covid-19 symptoms not yet requiring hospitalisation.
Read moreSynairgen makes solid progress with Covid-19 treatment
18th Dec 2020 10:29
(Sharecast News) - Respiratory drug development company Synairgen updated the market on its phase 3 trial design evaluating SNG001 as a treatment for patients with Covid-19 on Friday, as well as positive progress on its regulatory path.
Read moreSynairgen surges on positive results for Covid-19 treatment
13th Nov 2020 14:28
(Sharecast News) - Synairgen shares surged on Friday after data from trials of its inhaled Covid-19 treatment, SNG001, published in The Lancet Respiratory Medicine, showed positive results in hospitalised patients.
Read moreSynairgen files for another patent on 'SNG001'
9th Sep 2020 12:23
(Sharecast News) - Respiratory drug development company Synairgen updated the market on its intellectual property for the wholly-owned inhaled interferon beta asset 'SNG001' on Wednesday.
Read moreSynairgen upbeat on latest data from SNG001 trials
8th Sep 2020 15:16
(Sharecast News) - Respiratory drug discovery and development company Synairgen announced positive data from the interim analysis of its exploratory phase 2 clinical trial of inhaled 'SNG001' on Tuesday, in chronic obstructive pulmonary disease (COPD) patients with a confirmed respiratory viral infection.
Read more